CN202

Curon Biopharmaceutical (Australia) Co Pty Ltd · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	CN202
Sponsor	Curon Biopharmaceutical (Australia) Co Pty Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CN202 CI brief — competitive landscape report
CN202 updates RSS · CI watch RSS
Curon Biopharmaceutical (Australia) Co Pty Ltd portfolio CI